Background
Treatment with thyroid hormones is occasionally used in the management of treatment‐resistant depression. However, the evidence supporting this treatment is not fully established. The aim of this study was to systematically review the literature on the effect of adjunctive thyroid hormone in the management of treatment‐resistant unipolar depression and to provide a pooled estimate of its efficacy.
Methods
The study is registered with PROSPERO (reg. no. CRD42018108088) and followed the PRISMA guidelines. Searches were carried out on June 24, 2019, in PubMed, EMBASE, and PsycINFO. Each record was screened independently by at least two reviewers. In instances of discrepancies, consensus was reached upon discussion. Pooled efficacy estimates were calculated based on response rates (decrease of ≥50% on the primary outcome measure) using random effect statistics.
Results
The search yielded 1355 records. Based on the screening of these records, we identified 10 studies that met the inclusion criteria (total number of patients = 663). The comparison of response to thyroid hormones vs. placebo resulted in an odds ratio of 1.56 (95% CI: 0.50–4.84). Similarly, the comparison of response to thyroid hormones vs. lithium resulted in an odds ratio of 1.91 (95% CI: 0.85–4.26). Thus, adjunctive therapy with thyroid hormones was not superior to placebo or lithium in the management of treatment‐resistant unipolar depression.
Conclusion
According to this review and meta‐analysis, there is not sufficient evidence to support the use of adjunctive thyroid hormones for treatment‐resistant unipolar depression.